| Business

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

Email Newsletters

Sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Business Headlines

  1. As historic breakup nears, Alcoa works to redefine its ‘advantage’
  2. Batteries key to alternative energy’s success
  3. Asian bug threatens oranges in Florida
  4. Make green home upgrades pay off
  5. Older workers try to cut back on hours at job
  6. Paying pals digitally catches on
  7. Program lets public service workers be forgiven for student debt
  8. Travelers contend with increase  in ground delays
  9. Black Friday chaos dwindles thanks to earlier deals, online sales
  10. Stocks close quiet week with little change
  11. Small stores take big gamble by not upgrading credit card readers